| Literature DB >> 24325681 |
Abstract
The traditional microscope, together with the "routine" hematoxylin and eosin (H & E) stain, remains the "gold standard" for diagnosis of cancer and other diseases; remarkably, it and the majority of associated biological stains are more than 150 years old. Immunohistochemistry has added to the repertoire of "stains" available. Because of the need for specific identification and even measurement of "biomarkers," immunohistochemistry has increased the demand for consistency of performance and interpretation of staining results. Rapid advances in the capabilities of digital imaging hardware and software now offer a realistic route to improved reproducibility, accuracy and quantification by utilizing whole slide digital images for diagnosis, education and research. There also are potential efficiencies in work flow and the promise of powerful new analytical methods; however, there also are challenges with respect to validation of the quality and fidelity of digital images, including the standard H & E stain, so that diagnostic performance by pathologists is not compromised when they rely on whole slide images instead of traditional stained tissues on glass slides.Entities:
Keywords: Biological Stain Commission; Food and Drug Administration; biological stains; companion diagnostics; diagnosis; digital images; digital pathology; formalin fixation; immunohistochemistry; paraffin embedding; predictive markers; primary diagnosis; regulatory issues; reproducibility; validation; whole slide imaging
Mesh:
Substances:
Year: 2013 PMID: 24325681 DOI: 10.3109/10520295.2013.861512
Source DB: PubMed Journal: Biotech Histochem ISSN: 1052-0295 Impact factor: 1.718